GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Cyclically Adjusted PB Ratio

Predictive Oncology (Predictive Oncology) Cyclically Adjusted PB Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Predictive Oncology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted PB Ratio Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Predictive Oncology's Cyclically Adjusted PB Ratio

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted PB Ratio falls into.



Predictive Oncology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Predictive Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Predictive Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.998/131.7762*131.7762
=0.998

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201406 -5,464.407 100.560 -7,160.724
201409 -6,391.667 100.428 -8,386.817
201412 -8,896.774 99.070 -11,833.922
201503 -8,801.587 99.621 -11,642.510
201506 -9,309.091 100.684 -12,183.841
201509 5,572.115 100.392 7,314.087
201512 3,936.538 99.792 5,198.212
201603 236.995 100.470 310.841
201606 50.450 101.688 65.377
201609 0.646 101.861 0.836
201612 40.447 101.863 52.325
201703 122.712 102.862 157.206
201706 103.328 103.349 131.749
201709 73.203 104.136 92.633
201712 77.333 104.011 97.977
201803 88.360 105.290 110.588
201806 55.600 106.317 68.914
201809 45.171 106.507 55.888
201812 0.738 105.998 0.917
201903 0.795 107.251 0.977
201906 143.708 108.070 175.233
201909 131.297 108.329 159.715
201912 55.194 108.420 67.084
202003 35.263 108.902 42.670
202006 17.724 108.767 21.473
202009 14.748 109.815 17.697
202012 2.668 109.897 3.199
202103 14.569 111.754 17.179
202106 16.251 114.631 18.682
202109 14.600 115.734 16.624
202112 12.273 117.630 13.749
202203 11.282 121.301 12.256
202206 8.581 125.017 9.045
202209 7.548 125.227 7.943
202212 5.527 125.222 5.816
202303 4.673 127.348 4.835
202306 3.670 128.729 3.757
202309 2.888 129.860 2.931
202312 2.036 129.419 2.073
202403 0.998 131.776 0.998

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Predictive Oncology  (NAS:POAI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Predictive Oncology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121

Predictive Oncology (Predictive Oncology) Headlines

From GuruFocus